Management and Outcomes of HIV-Associated Primary Effusion Lymphoma: A Single Center Experience
Conclusions Given its rarity, our knowledge of PEL relies solely on case reports and case series. Prompt HAART and chemotherapy may be effective in HIV- associated PEL and good outcomes are possible. LDH and CD4 may be possible prognostic factors in PEL. Micro-Abstract Primary effusion lymphoma (PEL) is a rare form of lymphoma, primarily seen in individuals who are immunosuppressed. We studied all cases of PEL seen at our institution over a 15-year period and observed that if affected mostly male patients with HIV who were not taking the antiretroviral medication. Newer chemotherapy regimens including the drug bortezomib m...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Lymphomatoid Granulomatosis: A Single Institution Experience and Review of the Literature
Conclusions LYG is a rare B-cell lymphoproliferative disorder with involvement if the respiratory system. The presentation is heterogeneous, and response to therapy is variable. Although it is considered a poor prognosis disease, long-term survivors in remission have been described. Micro-Abstract Lymphomatoid granulomatosis is a rare B-cell lymphoproliferative disorder characterized by involvement of the respiratory system and frequently associated with EBV infection. In this study we present the general characteristics in a single institution. Treatment with rituximab based-chemotherapy was effective with long term respo...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Human Herpesvirus Type 8-positive Multicentric Castleman Disease
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Anait L. Melikyan, Elena K. Egorova, Hunan L. Julhakyan, Alla L. Kovrigina, Valeriy G. Savchenko Castleman disease (CD) is rare lymphoproliferative disorder with local lesionsor with multiple lessions (multicentric CD [MCD]–usually with plasma cell or mix cell morphology). Patients with human herpesvirus (HHV) type 8-positive MCD were included in a separate group owing to its extremely aggressive course and the high risk of transformation into HHV8+ plasmablastic lymphoma. At our hematologic center, from 199...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

The Prognostic Significance of Elevated Serum Ferritin Levels Prior to Transplantation in Patients With Lymphoma Who Underwent Autologous Hematopoietic Stem Cell Transplantation (autoHSCT): Role of Iron Overload
Conclusion Elevated serum ferritin levels might predict poorer survival in autoHSCT recipients. Micro-Abstract Transfusional iron overload (IO) is considered to be a significant problem hematopoietic stem cell transplantation (HSCT) recipients. Patients with IO have poorer outcomes compared to those with normal iron stores. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Successful Nonsurgical Eradication of Invasive Gastric Mucormycosis
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Georges El Hachem, Nabil Chamseddine, Ghada Saidy, Camil Choueiry, Claude Afif (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Is Maintenance Therapy for Everyone?
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Ajay K. Nooka, Sagar Lonial Although myeloma remains an incurable disease among majority of myeloma patients, the prognosis has significantly improved after the introduction of novel agents. While more agents are being explored for their anti-myeloma activity, the more familiar agents with a better tolerability profile have been tested in the maintenance arena. Lenalidomide and bortezomib so far have shown promise as effective maintenance agents in prolonging PFS, and also OS in some studies. The current review ai...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

How to Think About Risk in Myeloma
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Amrita Krishnan An integral part of myeloma therapy is risk stratification of newly diagnosed patients. This method involves a combination of staging and genetic risk assessment. Although survival has dramatically improved for patients with genetically defined, standard-risk myeloma, those with high-risk disease remain a therapeutic challenge. Current treatment approaches might include the use of combination therapy for induction and maintenance. Future approaches are expected to involve drugs that are “risk...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Clonal Evolution in Multiple Myeloma
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Bita Fakhri, Ravi Vij Multiple myeloma (MM) is the second most common hematologic malignancy encountered among patients in the United States. The last decade has seen incremental improvements in the survival of patients with MM. These advances are, to a large extent, attributable to the addition of proteasome inhibitors and immunomodulatory drugs to the armamentarium of treatment options. The adoption of these drug classes was the result of an empiric research paradigm. However, with the application of next genera...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): John Mascarenhas Myeloproliferative neoplasms (MPN) in chronic phase that evolve into blast phase (BP) hold a dismal prognosis and represent an urgent unmet clinical need. The mutational landscape of MPN-BP is distinct from de novo acute myeloid leukemia and offers insight into molecular mechanisms contributing to clonal evolution providing potential novel drug targets. A number of retrospective studies have identified patient- and disease-specific variables associated with increased risk of leukemic transformatio...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

How to Treat Essential Thrombocythemia and Polycythemia Vera
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Carlos Besses, Alberto Alvarez-Larrán Polycythemia vera and essential thrombocythemia (ET) are chronic myeloproliferative neoplasms associated with thrombotic or hemorrhagic complications, and increased risk of transformation to myelofibrosis and acute myeloid leukemia. The main goal of therapy is aimed at preventing vascular events that are the leading cause of morbidity and mortality in these patients. Accordingly, risk stratification is the basis for deciding when to treat a patient with cytoreductive th...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Prognosis of Primary Myelofibrosis in the Genomic Era
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Prithviraj Bose, Srdan Verstovsek Currently, prognostication in primary myelofibrosis (PMF) relies on the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus, which incorporate age, blood counts, constitutional symptoms, circulating blasts, red cell transfusion need, and karyotype. Although the JAK2 V617F mutation was discovered a decade ago and MPL mutations shortly thereafter, it was the recent discovery of CALR mutations in the vast majority of JAK2/MPL-unmutated patients and re...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

When to Consider Allogeneic Transplantation in CML
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Jerald Radich Tyrosine kinase inhibitor (TKI) therapy has radically altered the treatment strategy for chronic myeloid leukemia. Allogeneic transplantation, which over a decade ago was considered the definitive therapy for CML, is now appropriately used in cases where all TKIs are not tolerated, in cases of resistance to TKI therapy, or when the disease progresses from chronic phase to accelerated or blast phase. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Multiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Conclusion These findings suggest that dasatinib therapy (within the therapeutic range) can increase trabecular bone, without causing significant changes in bone and mineral metabolism. Nonetheless, monitoring of bone health and skeletal integrity should be included into the long-term management of patients treated with dasatinib to further enhance our understanding of its safety profile and its potential role as a treatment modality for other bone diseases. Micro-Abstract We assessed patients with chronic myelogenous leukemia for serum Ca, PO4, bone alkaline phosphatase, N-telopeptide, osteoprotegerin levels and trabecula...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Imatinib Intolerance Is Associated With Blastic Phase Development in Philadelphia Chromosome –Positive Chronic Myeloid Leukemia
Conclusion Most imatinib-intolerant patients develop blastic phase transformation, with a poor survival of 3 to 6 months; no effective rescue treatment is available. Future research should to determine whether the origin of this evolution is really due to the intolerance itself or whether it is due to a more aggressive form of the disease, perhaps related to genetic transformation. Micro-Abstract The overall prognosis of Philadelphia chromosome–positive chronic myeloid leukemia patients is today considered to be good thanks to targeted therapy with tyrosin kinase inhibitors (TKIs). A study of a 86-patient cohort show...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Treatment of Chronic Lymphocytic Leukemia With del(17p)/TP53 Mutation: Allogeneic Hematopoietic Stem Cell Transplantation or BCR-Signaling Inhibitors?
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Emili Montserrat, Peter Dreger The treatment of patients with chronic lymphocytic leukemia (CLL) whose tumor presents the del(17p)/TP53 mutation is a major challenge. Treatment with chemo(immuno)therapy, immunomodulators, or the anti-CD52 monoclonal antibody alemtuzumab produces transient, unsatisfactory responses. Reduced-intensity-conditioning allotransplantation produces sustained progression-free survival and overall survival (40%-60% at 5 years), equivalent to the cure of the disease, even in cases with adver...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Conclusion These results should be confirmed in a larger patient cohort. PDE4 expression could be an effective potential prognostic factor and therapeutic target for patients with MDS and chronic myelomonocytic leukemia. The role of PDE4 inhibitors should be explored in vitro against MDS cell lines and in preclinical mouse models of MDS. Micro-Abstract PDE4 expression control the inflammation which has an essential role in the pathogenesis of myelodysplastic syndromes (MDS). The expression of each isoform of the PDE4 was evaluated, using transcriptomic profiling, from healthy individuals (n = 10) and patients with MDS (n =...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale
Conclusion Further clinical studies are needed to identify patients with CMML who will benefit from this treatment. Micro-Abstract In a phase I dose-escalation study using eltrombopag to treat patients with myelodysplastic syndromes after hypomethylating agents failure, we observed that patients with chronic myelomonocytic leukemia may respond to eltrombopag. However, use in a subset of chronic myelomonocytic leukemia patients may be limited owing to leukocytosis and circulating blasts. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Trends in Clinical Investigation for Myelodysplastic Syndromes
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Thomas Prebet, Amer Zeidan Myelodysplastic syndrome (MDS) paradigms have been dramatically changed over the last 10 years by major breakthroughs on both pathophysiologic and therapeutic aspects. It is currently a field of intense clinical investigation as new challenges have emerged in both low-risk and high-risk populations. In low-risk MDS, long-term control of anemia is a major issue, and second-line treatments after failure of erythropoiesis-stimulating agents are warranted. Several promising therapies are ava...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience
Conclusion MDS is rare and tends to be more aggressive in the AYA population. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation offered younger patients the best outcomes. Micro-Abstract Little is known regarding myelodysplastic syndromes (MDS) in the younger population. This retrospective review reviewed the characteristics, outcomes, and response to treatment in the adolescent and young adult (AYA) population compared to an older population. MDS was found to be rare and more aggressive in AYA. Karyotype was the most important prognostic factor. Allogeneic stem-cell transplantation o...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Asmita Mishra, Claudio Anasetti Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative option for patients with myelodysplastic syndrome (MDS). Because MDS predominantly affects an older population, age-associated comorbidities can preclude patients from cure. HSCT is associated with the risk of morbidity and mortality; however, with safer conditioning regimens and improved supportive care, eligible patients with an appropriately matched donor can receive this therapy without exclusion...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Immunosuppressive Therapy: Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome
Conclusion IST has a hematologic improvement response rate in the range of other therapies approved for lower risk MDS. High risk IPSS-R, poor karyotype, and treatment after 2 years from diagnosis have unfavorable response trend. ATG with CSA has higher response than ATG alone. First-line ATG or after lenalidomide had better response trend compared to third-line therapy or azacitidine therapy. Micro-Abstract Immunosuppresive therapy in low risk myelodysplastic syndrome can achieve sustained hematologic improvement but is underutilized due to lack of selection criteria. We completed a retrospective analysis of sixty-six pat...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Rami S. Komrokji The higher risk myelodysplastic syndrome (MDS) patients, defined by the International Prognostic Scoring System (IPSS) as intermediate-2 or high-risk groups, compromise a third of MDS patients who have an expected survival of less than 1.5 years. Our ability to better define higher risk MDS improved with the proposal of new clinical risk models such as the revised IPSS and by integration of molecular data, including somatic gene mutations. Allogeneic hematopoietic stem-cell transplantation (AHSCT)...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing  Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
We examined the expression of HDM4 and the short splicing variant, HDM4-S, in bone marrow samples obtained from 85 and 23 patients with AML and MDS, respectively, and 18 negative tumor staging bone marrow samples (used as the control). Immunohistochemical staining showed that HDM4 was overexpressed in 78 AML cases (92%) and 12 MDS cases (52%) compared with 1 stressed bone marrow sample (6%). Quantitative reverse transcriptase-polymerase chain reaction analysis of 8 AML and 11 low-grade (LG)-MDS cases confirmed that HDM4 and HDM4-S mRNA expression were also elevated in all AML cases. HDM4 and HDM4-S mRNA expression was...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Acute Myeloid Leukemia: Past, Present, and Prospects for the Future
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Nicholas J. Short, Farhad Ravandi Dose intensification of chemotherapy and the combination of a third cytotoxic agent with standard cytarabine and anthracycline-based induction chemotherapy have led to improved outcomes in select groups of patients with acute myeloid leukemia (AML). However, despite some progress in this area, it appears that we might be reaching the limit of cytotoxic chemotherapy for the treatment of AML, especially in older patients and in those with poor-risk features whose disease tends to be...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia
Conclusion There is a significant correlation between some markers, and certain ALL recurrent cytogenetic subgroups (CD123 and hyperdiploidy, CD79b negativity, and ETV-RUNX1 group) have good prognostic value. CD200 can be used as MRD markers in ALL patients and can also can serve as therapy targets. Micro-Abstract ALL is the most common childhood malignancy and identification of prognostic factors is important for further improvement of the treatment outcome in this fatal disease. Cytogenetic changes and MRD are the most powerful prognostic factors in ALL. We identified significant correlations between some CD markers and ...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Increased Hepatic Iron Content Predicts Poor Survival in Patients With Iron Overload Who Underwent Allogeneic Hematopoietic Stem Cell Transplantation
Conclusion Hepatic iron content might be associated with poorer prognosis in patients with iron overload that underwent alloHSCT. Micro-Abstract Transfusional iron overload remains a serious problem in alloHSCT setting. Liver is among the most common organs that iron accumulate. The degree of hepatic iron content might be associated with poorer survival in alloHSCT recipients. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Perspectives and Future Directions for Acute Lymphoblastic Leukemia
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Anjali S. Advani (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Blinatumomab: Bridging the Gap in Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Stephanie A. Folan, Amber Rexwinkle, Jane Autry, Jeffrey C. Bryan Adult patients with acute lymphoblastic leukemia who relapse after frontline therapy have extremely poor outcomes despite advances in chemotherapy and hematopoietic stem cell transplantation. Blinatumomab is a first-in-class bispecific T-cell engager that links T cells to tumor cells leading to T-cell activation and tumor cell lysis. In December 2014, the Food and Drug Administration approved blinatumomab for treatment of relapsed or refractory Phil...
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology
Publication date: August 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Supplement Author(s): Alan F. List, Hagop Kantarjian, Emil J. Freireich (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - August 8, 2016 Category: Cancer & Oncology Source Type: research

Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia
Conclusion AlloHCT2 remains a potential curative option in a subset of patients with relapsed ALL after the first AlloHCT. Micro-Abstract The outcome of patients with acute lymphoblastic leukemia relapsing after first allogeneic hematopoietic cell transplantation remains poor. A second transplant is a potential curative option for a subset of patients. Patients with relapse within the first year after allogeneic hematopoietic cell transplantation should preferably be enrolled in a clinical trial of novel therapies. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Continued Role of Splenectomy in the Management of Patients With Myelofibrosis
Publication date: Available online 8 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Daniel Aruch, Myron Schwartz, John Mascarenhas, Marina Kremyanskaya, Carrie Newsom, Ronald Hoffman (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Post-Transplantation Natural Killer Cell Count: A Predictor of Acute Graft-Versus-Host Disease and Survival Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation
Conclusion NK cell counts after allo-HSCT, especially on day 30, were predictive of acute graft-versus-host disease, nonrelapse mortality, and survival. Serial lymphocyte subset analysis can be used to identify and treat patients at risk during the early period after allo-HSCT. Micro-Abstract Reconstitution of the immune system after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is important in transplant outcomes. We retrospectively analyzed the data from 70 patients who had undergone allo-HSCT with the lymphocyte subset results. Also, the association between the lymphocyte subset counts and early compli...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Diffuse Large B-Cell Lymphoma in the Elderly: Real World Outcomes of Immunochemotherapy in Asian Population
Conclusion Elderly patients aged < 75 years were able to tolerate standard immunochemotherapy, with acceptable survival profiles. In an Asian population, 75 years seems to be a judicious cutoff for predicting treatment outcomes. Micro-Abstract We evaluated the real-life treatment outcomes of elderly patients with diffuse large B-cell lymphoma from an Asian population. The medical records of 192 patients aged > 60 years who had received first-line immunochemotherapy were retrospectively analyzed. Elderly patients < 75 years old tolerated standard immunochemotherapy, with acceptable survival p...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Anaplastic Multiple Myeloma: An Aggressive Variant With a Poor Response to Novel Therapies
Publication date: Available online 8 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Nischala Ammannagari, Kimberly Celotto, Vishala Neppalli, Kelvin Lee, Sarah A. Holstein (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Nonadherent Spheres With Multiple Myeloma Surface Markers Contain Cells that Contribute to Sphere Formation and Are Capable of Internalizing Extracellular Double-Stranded DNA
Conclusion Nonadherent 3-D cell colonies (spheres) encompass B cells with CD73/CD20+/CD45+/CD19dim phenotype, as well as double-stranded DNA-internalizing cells. The latter cell type appears to function as a sphere-forming center. Different cells in the spheres communicate with each other by secreting specific sets of cytokines. For successful engraftment and tumor growth in mice, intact spheres containing ∼ 106 cells must be used. Micro-Abstract We present phenotypic analysis of free-floating spheres derived from the bone marrow clonogenic aspirate of a multiple myeloma patient. Besides CD73/CD20+/CD45+/CD19dim B cel...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

FLT3 Inhibitors for Treating Acute Myeloid Leukemia
Publication date: Available online 25 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Mona Hassanein, Muhamad H. Almahayni, Syed O. Ahmed, Sameh Gaballa, Riad El Fakih FLT3 (Fms-like tyrosine kinase 3) inhibitors are tyrosine kinase inhibitors. The first-generation FLT3 inhibitors were developed several years ago and include midostaurin, lestaurtinib, sunitinib, and sorafenib. They are relatively nonspecific for FLT3, with other potential targets that include platelet-derived growth factor receptor, vascular endothelial growth factor receptor, KIT, and Janus kinase 2. The second-generation inhibit...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Validation and Utility of the Free Light Chain Assay in Pleural Effusions of Patients With Multiple Myeloma
Publication date: July 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Issue 7 Author(s): Thomas U. Marron, Matthew G. Hanna, Lakshmi Ramanathan, Ajai Chari (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Survival of Subcutaneous Panniculitis-Like T-Cell Lymphoma and Peripheral T-Cell Lymphoma Not Otherwise Specified: A Propensity-Matched Analysis of the Surveillance, Epidemiology, and End Results Database
Conclusion Our study provides characteristics and OS of a large cohort of SPTCL. Compared with PTCL NOS, SPTCL patients were more likely to be younger, female, and diagnosed at an early stage. The OS of SPTCL was better than PTCL NOS. Micro-Abstract Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of peripheral T-cell lymphoma (PTCL) with limited studies. We used the Surveillance, Epidemiology, and End Results 18 registry to identify a cohort of unselected patients with SPTCL and compared its outcomes with patients with PTCL not otherwise specified (NOS), the most common subtype among all PTCL. The...
Source: Clinical Lymphoma Myeloma and Leukemia - July 28, 2016 Category: Cancer & Oncology Source Type: research

Extramedullary Cardiac Multiple Myeloma —A Case Report and Contemporary Review of the Literature
We present the case of a 61-year-old female patient 47 days after autologous stem cell transplant for MM who developed cardiac tamponade owing to extramedullary recurrence of myeloma, pulmonary embolism, and takotsubo cardiomyopathy. We performed a review of the published studies of all cases of MM presenting at diagnosis or relapse with cardiac or pericardial involvement in the past 25 years. Including our patient, 34 patients with plasmacytoma involving cardiac or pericardial structures were identified from the literature search. Approximately equal numbers of patients were male and female (42% and 57%, respectively). Th...
Source: Clinical Lymphoma Myeloma and Leukemia - June 17, 2016 Category: Cancer & Oncology Source Type: research

Volume –Outcome Relationships in Pediatric Acute Lymphoblastic Leukemia: Association Between Hospital Pediatric and Pediatric Oncology Volume With Mortality and Intensive Care Resources During Initial Therapy
Conclusion Induction mortality was low. We did not observe an inverse relationship between volume and mortality or ICU care. This suggests that in a modern treatment era, treatment at a low-volume center might not be associated with increased mortality or ICU care in the first portion of therapy. This relationship should be evaluated in other oncology populations with higher mortality rates and with longer-term outcomes. Micro-Abstract A volume–outcome relationship has been shown in adult oncology. We investigated if an inverse association of volume and death exists in pediatric acute lymphoblastic leukemia (ALL) ca...
Source: Clinical Lymphoma Myeloma and Leukemia - June 17, 2016 Category: Cancer & Oncology Source Type: research

Can We Cure Light Chain Deposition Disease of the Kidneys? —A Review and Case Report of a Patient Treated With a Triple Transplant Approach
Publication date: June 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Issue 6 Author(s): Dharshan Sivaraj, Michael Martin Green, Abdullah Mucahit Ciftci, Mohammad Faizan Zahid, Angela Anne Johns, Maureen Ross, Cristina Gasparetto (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 17, 2016 Category: Cancer & Oncology Source Type: research

Outcome Disparities in Caucasian and  Non-Caucasian Patients With Myeloproliferative Neoplasms
Conclusion This study shows for the first time that race can influence clinical outcomes in myeloproliferative neoplasms. Our findings highlight the need for greater representation of non-Caucasian patients in studies investigating vascular risk factors in MPNs. Micro-Abstract This is a single institution retrospective experience examining the effect of race and ethnicity on disease phenotype in myeloproliferative neoplasms. We demonstrate racial disparities in the outcomes of myeloproliferative neoplasm, with Caucasian ethnicities being relatively protected against cardiovascular thrombosisis and hemorrhagic complication...
Source: Clinical Lymphoma Myeloma and Leukemia - June 17, 2016 Category: Cancer & Oncology Source Type: research

What to do with success? The optimist ’s creed in relapsed Hodgkin lymphoma
Publication date: Available online 8 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Amir Issa, Jason Westin Checkpoint inhibitors have demonstrated remarkable efficacy in patients with chemotherapy resistant Hodgkin lymphoma. However, it remains unclear if these impressive agents have curative potential, or if relapse and death will eventually occur. In this review, we discuss the options for a therapeutic dilemma which is likely to occur with increasing frequency, what to do for a Hodgkin lymphoma patient who is responding the checkpoint inhibitors? We discuss the four most likely considered option...
Source: Clinical Lymphoma Myeloma and Leukemia - June 17, 2016 Category: Cancer & Oncology Source Type: research

Canonical Wnt/ β-catenin signaling pathway is dysregulated in patients with primary and secondary myelofibrosis
Conclusion Present study shows for the first time that β-catenin mRNA expression is increased in patients with both PMF and SMF and its upregulation might potentiate anemia. Number of inflammatory cytokines associated with PMF are capable of mediating their effects through increased β-catenin expression. Accordingly, β-catenin can induce expression of number of genes implicated in processes of cell cycle control, fibrosis and angiogenesis which are central to the PMF pathogenesis. Therefore, β-catenin may represent interesting new therapeutic target in these diseases. Graphical abstract Teaser Activatio...
Source: Clinical Lymphoma Myeloma and Leukemia - June 17, 2016 Category: Cancer & Oncology Source Type: research

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions
Publication date: Available online 16 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): S. Bhalla, D. Tremblay, J. Mascarenhas BCR-ABL1 tyrosine kinase inhibitors (TKIs) have dramatically transformed the treatment of patients with chronic myelogenous leukemia (CML). Given the impressive and sustained response to TKI therapy the majority of treated CML patients enjoy, recent studies have explored the potential to achieve treatment free remission (TFR) in select patients, which may allow these patients to escape the adverse clinical and financial effects associated with life-long TKI therapy. The result...
Source: Clinical Lymphoma Myeloma and Leukemia - June 15, 2016 Category: Cancer & Oncology Source Type: research

Can We Cure Light Chain Deposition Disease of the Kidneys?—A Review and Case Report of a Patient Treated With a Triple Transplant Approach
Publication date: June 2016 Source:Clinical Lymphoma Myeloma and Leukemia, Volume 16, Issue 6 Author(s): Dharshan Sivaraj, Michael Martin Green, Abdullah Mucahit Ciftci, Mohammad Faizan Zahid, Angela Anne Johns, Maureen Ross, Cristina Gasparetto (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 13, 2016 Category: Cancer & Oncology Source Type: research

Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience
Conclusion Bortezomib is a safe and well-tolerated therapy for patients with AL amyloidosis with a rapid hematologic response and cardiac response, as assessed by the NT-proBNP level. Micro-Abstract Bortezomib exhibits unprecedented single-agent activity in AL amyloidosis. Here, we performed a review of the use of bortezomib containing regimens to assess the rapidity and quality of response. After a median of 4 cycles, a HR was seen in 49/52 cases (94.2%) demonstrating that bortezomib is a safe and well-tolerated therapy for AL patients showing rapid HR and cardiac responses. (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 13, 2016 Category: Cancer & Oncology Source Type: research

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia
Conclusion Dasatinib could be an appropriate treatment option for imatinib-intolerant patients with CML, with cross-intolerance resulting in discontinuation in a few patients. Micro-Abstract Some patients with chronic myeloid leukemia (CML) are intolerant to first-line imatinib treatment. Our retrospective data analysis of 271 CML imatinib-intolerant patients from phase II and III studies examined the extent of cross-intolerance between imatinib and dasatinib. Our results have confirmed the clinical safety and efficacy of dasatinib in imatinib-intolerant CML patients, suggesting that dasatinib could be a suitable treatmen...
Source: Clinical Lymphoma Myeloma and Leukemia - June 13, 2016 Category: Cancer & Oncology Source Type: research

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
Conclusion Maintenance TKI therapy after transplantation is feasible and might reduce the incidence of relapses and improve outcomes after allogeneic hematopoietic stem cell transplantation for patients with high-risk Ph+ leukemia. Micro-Abstract Relapse is the major cause of allogeneic hematopoietic stem cell transplantation failure in high-risk Philadelphia chromosome-positive (Ph+) leukemia. Post-transplant maintenance therapy is a promising strategy. We found maintenance imatinib and dose-reduced newer generation tyrosine kinase inhibitors to be feasible and generally well tolerated. This approach might reduce the inc...
Source: Clinical Lymphoma Myeloma and Leukemia - June 10, 2016 Category: Cancer & Oncology Source Type: research

Survival of Secondary Central Nervous System Lymphoma Patients in the Rituximab Era
Publication date: Available online 8 June 2016 Source:Clinical Lymphoma Myeloma and Leukemia Author(s): Megan M. Herr, Nimish A. Mohile, Paul M. Barr, Edwin van Wijngaarden, Edward B. Brown, David Q. Rich (Source: Clinical Lymphoma Myeloma and Leukemia)
Source: Clinical Lymphoma Myeloma and Leukemia - June 8, 2016 Category: Cancer & Oncology Source Type: research